The table below shows Kiniksa Pharmaceuticals, Ltd.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$677.56M
$423.24M
$270.26M
$220.18M
$38.54M
-
Cost of revenue
$77.67M
$60.91M
$33.41M
$22.89M
$9.10M
-
Gross profit
-
-
-
-
-
-
R&D
$96.85M
$111.62M
$76.10M
$65.49M
$99.30M
$112.04M
SG&A
KNSA annual revenue (10-K history)
Kiniksa Pharmaceuticals, Ltd. reported annual revenue of $677.56M for fiscal year 2025. That is up 60.1% from $423.24M in fiscal 2024. Over the 5 fiscal years shown, annual revenue grew from $38.54M (FY 2021) to $677.56M. Figures come from the company's audited annual reports as filed with the SEC.